SUBSCRIBE TODAY!
Subscribing entitles a reader to complete stories on all topics released as they happen, special features, confidential documents and access to the complete, searchable story archive online back to 2004.
IP-Watch Summer Interns

IP-Watch interns talk about their Geneva experience in summer 2013. 2:42.

Inside Views

Submit ideas to info [at] ip-watch [dot] ch!

We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

Latest Comments
  • So simply put, we have the NABP saying that all ph... »
  • The original Brustle decision was widely criticise... »

  • For IPW Subscribers

    A directory of IP delegates in Geneva. Read more>

    A guide to Geneva-based public health and intellectual property organisations. Read More >


    Monthly Reporter

    The Intellectual Property Watch Monthly Reporter, published from 2004 to January 2011, is a 16-page monthly selection of the most important, updated stories and features, plus the People and News Briefs columns.

    The Intellectual Property Watch Monthly Reporter is available in an online archive on the IP-Watch website, available for IP-Watch Subscribers.

    Access the Monthly Reporter Archive >

    El Patent Pool estimula las perspectivas de medicamentos anti-VIH con una primera Licencia

    Published on 13 July 2011 @ 3:16 pm

    By , Intellectual Property Watch

    El Medicines Patent Pool y la compañía farmacéutica Gilead Sciences ha anunciado hoy un acuerdo de licencia para permitir la producción medicamentos clave para el combate contra el VIH a un menor costo y en una formulación más fácil de usar, haciéndolos más accesibles a los países en desarrollo. El acuerdo se extiende al uso de tratamientos para la hepatitis B por primera vez.

    “El día de hoy marca un hito en la gestión de patentes para salud pública” señalo la Directora Ejecutiva del Medicines Patent Pool Ellen ‘t Hoen en un comunicado de prensa “La gente en los países en desarrollo a menudo tienen que esperar durante años antes de poder tener acceso a nuevs tecnologías sanitarias. El acuerdo de hoy lo ha cambiado”

    “En particular”, manifestó ‘T Hoen, “las licencias de Elvitegravir, Cobicistat y el “Quad” [una combinación de cuatro medicamentos], si bien aun se encuentran en fase de desarrollo clínico deberían acelerar significativamente la disponibilidad”. La licencia permitirá a versiones genéricas de medicamentos patentados entrar en mercados poco después de que estén disponibles en los países ricos, de acuerdo a responsables del Patent Pool.

    El comunicado de prensa del Patent Pool, elementos básicos de información y la licencia están disponibles aquí.

    La licencia puede ser considerado como un logro significativo para el Patent Pool , que surgió del mecanismo innovador de financiación/compra de medicamentos UNITAID el año pasado. La licencia también destaca por mantener el derecho a hacer uso de flexibilidades al régimen legal patentes en el marco legal del comercio internacional, incluyendo el uso de licencias obligatorias, garantizando la posibilidad a la empresa a retirarse si así lo desea.

    La empresa obtiene el beneficio de posibles nuevas aplicaciones de sus medicamentos patentados, y la buena voluntad derivada de un proyecto destinado a poblaciones en situación de vulnerabilidad. Recibirá regalías del orden del 5% ciento de las ventas de genéricos, renunciando a esa cantidad para cualquier nueva formulaciones pediátricas, manifestaron responsables del Patent Pool.

    “Creemos que Cartera común de patentes un mecanismo innovador para aumentar el acceso a medicamentos patentados de una manera que funcione para la industria farmacéutica y las personas que viven con el VIH”, dijo Gregg Alton, vicepresidente ejecutivo de Asuntos Meidcos y Corporativos en Gilead en el comunicado (en Inglés).

    El acuerdo cubre todas las patentes relacionadas con cinco productos: Tenofovir (TDF), Emtribicina (FTC), Elvitegravir (EVG), Cobicistat (COBI), y el Quad, que es una combinación de dosis fija [es decir varios medicamentos combinados en una píldora] conteniendo TDF-FTC-EVG-COBI.

    En algunos de estos medicamentos, los productos están todavía en proceso de desarrollo y experimentación , mientras que otros están cerca del final del periodo de protección patentaría , de acuerdo con la base de datos del Patent Pool.

    Las licencias permitirán el suministro de Tenofovir y Emtricitabina en 111 países, Cobicistat en 102 países, y Elvitegravir y el Quad en 99 países. Sin embargo, las licencias no incluyen a todos los países en desarrollo, advirtieron responsables del Patent Pool.

    El ámbito geográfico de las licencias cubre la mayoría de las personas en países de ingresos bajos y medio que viven con VIH, manifestó Katilin Mara, portavoz del Patent Pool.

    El secretariado de ECONMED ha contribuido con la traducción y la adición de algunos hyperlinks.

    William New may be reached at wnew@ip-watch.ch.

     

    Comments

    1. medicamentos genericos says:

      El gobierno brasileño ha anunciado recientemente que para finales de marzo del presente año 2012 ya estarán disponibles nueve millones de comprimidos de la versión genérica del tenofovir, uno de los medicamentos utilizados en el tratamiento contra el HIV/Sida y la hepatitis.

    2. Luís Sá says:

      Bravo Patent Pool, BRAVO Gilead! :-)
      Thank you for yr efforts.
      :-)))fhe ythingen

    3. Luís Sá says:

      Thanks!!!you all!


    Leave a Reply

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website. By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    We welcome your participation in article and blog comment threads, and other discussion forums, where we encourage you to analyse and react to the content available on the Intellectual Property Watch website.

    By participating in discussions or reader forums, or by submitting opinion pieces or comments to articles, blogs, reviews or multimedia features, you are consenting to these rules.

    1. You agree that you are fully responsible for the content that you post. You will not knowingly post content that violates the copyright, trademark, patent or other intellectual property right of any third party or which you know is under a confidentiality obligation preventing its publication and that you will request removal of the same should you discover that you have violated this provision. Likewise, you may not post content that is libelous, defamatory, obscene, abusive, that violates a third party's right to privacy, that otherwise violates any applicable local, state, national or international law, that amounts to spamming or that is otherwise inappropriate. You may not post content that degrades others on the basis of gender, race, class, ethnicity, national origin, religion, sexual preference, disability or other classification. Epithets and other language intended to intimidate or to incite violence are also prohibited. Furthermore, you may not impersonate others.

    2. You understand and agree that Intellectual Property Watch is not responsible for any content posted by you or third parties. You further understand that IP Watch does not monitor the content posted. Nevertheless, IP Watch may monitor the any user-generated content as it chooses and reserves the right to remove, edit or otherwise alter content that it deems inappropriate for any reason whatever without consent nor notice. We further reserve the right, in our sole discretion, to remove a user's privilege to post content on our site. IP Watch is not in any manner endorsing the content of the discussion forums and cannot and will not vouch for its reliability or otherwise accept liability for it.

    3. By submitting any contribution to IP Watch, you warrant that your contribution is your own original work and that you have the right to make it available to IP Watch for all purposes and you agree to indemnify IP Watch, its directors, employees and agents against all damages, legal fees and others expenses that may be incurred by IP Watch as a result of your breach of warranty or of these terms.

    4. You further agree not to publish any personal information about yourself or anyone else (for example telephone number or home address). If you add a comment to a blog, be aware that your email address will be apparent.

    5. IP Watch will not be liable for any loss including but not limited to the following (whether such losses are foreseen, known or otherwise): loss of data, loss of revenue or anticipated profit, loss of business, loss of opportunity, loss of goodwill or injury to reputation, losses suffered by third parties, any indirect, consequential or exemplary damages.

    6. You understand and agree that the discussion forums are to be used only for non-commercial purposes. You may not solicit funds, promote commercial entities or otherwise engage in commercial activity in our discussion forums.

    7. You acknowledge and agree that you use and/or rely on any information obtained through the discussion forums at your own risk.

    8. For any content that you post, you hereby grant to IP Watch the royalty-free, irrevocable, perpetual, exclusive and fully sub-licensable license to use, reproduce, modify, adapt, publish, translate, create derivative works from, distribute, perform and display such content in whole or in part, world-wide and to incorporate it in other works, in any form, media or technology now known or later developed.

    9. These terms and your posts and contributions shall be governed and interpreted in accordance with the laws of Switzerland (without giving effect to conflict of laws principles thereof) and any dispute exclusively settled by the Courts of the Canton of Geneva.

     

     
    Your IP address is 213.238.175.71